C5 and atypical hemolytic-uremic syndrome: Over the past decade, atypical HUS (aHUS) has emerged as a complement‐mediated thrombotic microangiopathy (CM‐TMA), for which novel therapies targeting terminal complement activation are used (e.g., the anti‐C5 monoclonal antibody eculizumab).